TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03747939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast (CC-10004) Placebo
Description: Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles
Study: NCT02143401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02076139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nyaditum resae® 10e4

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nyaditum resae® 10e5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Study: NCT00291928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A
Description: Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B
Description: Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
Study: NCT02686983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone and local anesthetic
Description: Infiltration of the greater occipital nerve .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone and local anesthetic
Description: Infiltration of the greater occipital nerve .
Study: NCT01525875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mg (one 500 mg capsule two times daily) of placebo.
Study: NCT00718744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardization of allergenic extract (Ch. arcuatus)
Description: Allergenic extract for cutaneous prick-test
Study: NCT00700999

Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine
Description: Paroxetine 20-40mg po QD for 12 weeks
Study: NCT01864200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalidae polyvalent immune fab (ovine)
Description: crotalidae antivenom

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study: NCT05256758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate Capsules
Description: 49 patients randomised to receive fenofibrate for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placental Lactogen
Description: 13 patients randomised to receive placebo for 6 months.
Study: NCT01815255

Intervention type: DRUG
Intervention: tenofovir (TDF)
Study: NCT04172571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: Anti-PD-1 antibody; IV infusion, 200 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
Study: NCT02147977

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study: NCT01641640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT02507739

Intervention type: OTHER
Group type: OTHER
Intervention: no possibility to walk during labor

Intervention type: OTHER
Group type: OTHER
Intervention: possibility to walk during labor
Study: NCT01541176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absence of corticotherapy post-transplantation
Description: No study treatment
Study: NCT02641327

Intervention type: DEVICE
Intervention: EarlySense (Passive monitoring)
Description: Passive contact-free monitoring

Intervention type: DEVICE
Intervention: EarlySense (Passive monitoring)
Description: Passive contact-free monitoring
Study: NCT04079218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Insert
Description: Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
Study: NCT02401152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink 1
Description: Sports drink with a specific source of CHO.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink 2
Description: Sports drink with a specific source of CHO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iso-caloric sports drink with maltodextrin as CHO source
Study: NCT02939677

Intervention type: OTHER
Group type: OTHER
Intervention: Targeted exercise
Description: 12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)
Study: NCT06700382

Intervention type: DRUG
Intervention: capecitabine
Description: different methods of treatment for capecitabine

Intervention type: DRUG
Intervention: capecitabine
Description: different methods of treatment for capecitabine
Study: NCT04150172

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg
Description: Test drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg
Description: Test drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide IR 100mg
Description: Reference Drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide IR 100mg
Description: Reference Drug
Study: NCT04255862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study: NCT01024127

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01971398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive FASD education brochure
Description: Exposure to a positive FASD education brochure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative FASD education brochure
Description: Exposure to a negative FASD education brochure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (a general women's health brochure)
Description: Exposure to a general women's health brochure
Study: NCT00698529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance training
Description: NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leader (POL)
Description: POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leader (POL)
Description: POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
Study: NCT00659646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge and levofloxacin
Description: Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin only
Description: levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
Study: NCT01541176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotherapy post-transplantation
Description: Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day.
Study: NCT02855502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02919865

Intervention type: DEVICE
Group type: OTHER
Intervention: MR perfusion imaging
Description: MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery.
Study: NCT04182542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
Study: NCT00237718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha, gamma, beta, and delta (mixed) tocopherols
Description: approximately 666 IU daily (1 pill) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: 600 mg daily (2 pills 300 mg each) for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for alpha lipoic acid; 2 pills daily for 6 months
Study: NCT03756896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT01733199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Summons of patients and filling questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Summons of patients and filling questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Summons of patients and filling questionnaire.
Study: NCT01615523

Intervention type: OTHER
Intervention: MRI, EEG and cognitive testing
Description: Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse

Intervention type: OTHER
Intervention: MRI, EEG and cognitive testing
Description: Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
Study: NCT03444155

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Panmol-B-Complex
Description: Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Vitamin B-Complex
Description: Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
Study: NCT00578929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Nasal Spray 0.6%
Description: Olopatadine HCl 1 or 2 sprays per nostril twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Nasal Spray 0.6%
Description: Olopatadine HCl 1 or 2 sprays per nostril twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle 1 or 2 sprays per nostril twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle 1 or 2 sprays per nostril twice daily
Study: NCT01657201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYP-1018 200mg
Description: SYP-1018 200mg, Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYP-1018 200mg
Description: SYP-1018 200mg, Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole 200mg, Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole 200mg, Intravenous administration
Study: NCT02784418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Total Occlusion Percutaneous Coronary Intervention
Description: Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
Study: NCT02535598

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal presentation
Description: All the material will be presented as plain text.
Study: NCT01256775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NCX-4016
Description: NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCX4016 placebo
Description: NCX4016 placebo b.i.d. for 6 months
Study: NCT02453113

Intervention type: OTHER
Group type: OTHER
Intervention: low power laser
Description: Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
Study: NCT02348138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
Study: NCT03309436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate protocol
Description: Take CC 100mg/d at the same time with Gn until hCG injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
Study: NCT02509689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Global Z-Score Neurofeedback Training
Description: The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions.
Study: NCT03736421

Intervention type: PROCEDURE
Intervention: Peripheral Intravenous Analysis (PIVA)
Description: Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV

Intervention type: PROCEDURE
Intervention: Peripheral Intravenous Analysis (PIVA)
Description: Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV

Intervention type: PROCEDURE
Intervention: Peripheral Intravenous Analysis (PIVA)
Description: Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV

Intervention type: PROCEDURE
Intervention: Non-invasive fluid response measure
Description: To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.

Intervention type: PROCEDURE
Intervention: Non-invasive fluid response measure
Description: To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise (PLR)
Description: Test to predict cardiac output and fluid responsiveness

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise (PLR)
Description: Test to predict cardiac output and fluid responsiveness

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise (PLR)
Description: Test to predict cardiac output and fluid responsiveness
Study: NCT02387021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infragluteal Sciatic nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infragluteal Sciatic nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Study: NCT02535598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced presentation
Description: The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal support
Description: Participants receive semi-standardized support once a week and there will be no formal training or competence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced support
Description: Participants are offered daily support through the internet from trained therapists.
Study: NCT02387021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT01670032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CD07223 1.5 % Topical Gel BID
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CD07223 1.5% Topical Gel TID
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: CD07223 vehicle gel BID
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: CD07223 vehicle gel TID
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15